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To assess the potential role of interleukin (IL)-7 in immuno-
therapy of human malignant melanoma, we have examined 
the lymphokine-activated killer (LAK) cell sensitivity of four 
human melanoma cell lines against LAK cells generated by 
IL-7 or IL-2. Lysis was determined by a 24-h cytotoxicity test 
using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT). All melanoma cell lines were susceptible to 
IL-7 - and IL-2 - generated LAK cells. The sensitivity of 
melanoma cells to IL-2 - induced LAK cells was higher com-
pared to IL-7 - induced LAK cells. At an effector target ratio 
of 20 : 1, the lysis by IL-7 - induced LAK cells ranged be-
tween 41 % and 52%, whereas IL-2 - induced lysis ranged 
between 80% and 94% (p < 0.01). IL-7 -induced LAK cells, 
however, showed almost no cytotoxicity towards HaCat 
keratinocytes and human umbilical vein endothelial cells 
(HUVECs). Immunophenotyping revealed a higher expres-
I mmunotherapy with interleukin (IL)-2, or combinations of IL-2 and lymphokine-activated killer (LAK) cells, has been particularly successful in certain tumors such as malignant melanoma and renal cell carcinoma [1- 3]. IL-2 treatment has, however, marked limitations because of severe clinical 
toxicity including fluid retention, pulmonary edema, hypotension, 
and anuria. These adverse effects are thought to be related to dam-
age of the vascular endothelium, known as vascular leakage syn-
drome [4-7]. 
IL-7 is a stroma-derived cytokine that has a number of biologic 
effects on lymphocytes. IL-7 was originally identified because of its 
ability to support the growth of pre-B cells in Whitlock-Witte bone 
marrow cultures [8]. In addition to its growth-promoting effect on 
pre-B cells, IL-7 has been shown to play an important role in the 
regulation of human T-lymphocyte development [9 -12]. Re-
cently, IL-7 has been shown to enhance the generation of cytotoxic 
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sion of the tac antigen (CD 25) on IL-7 - generated LAK 
cells, particularly those cells that were CD 56 negative or CD 
3 positive compared to IL-2 - induced LAK cells. In contrast, 
IL-2- generated LAK cells killed 62% of the HaCat kerati-
nocytes and 60% of the HUVECs. Secretion of tumor necro-
sis factor-alpha into culture supernatants was significantly 
higher in IL-2 - generated LAK cells compared to IL-7-
stimulated LAK cells (p < 0.01), whereas TNF-alpha levels 
of IL-7 -induced LAK cells were in the range of unstimu-
lated lymphocytes. Because nonspecific cytotoxicity against 
other normal cells such as keratinocytes and endothelial cells 
contributes to the dose-limiting side effects of immunother-
apy with IL-2, immunotherapy using IL-7 might be a better 
tolerated future alternative. Key words: LAK cells/cytotoxicity/ 
TNF-a/IL-2.] Invest DermatoI102:838-842, 1994 
T lymphocytes and LAK cells [13-15]. These studies were con-
ducted predominantly with the natural killer (NK)-sensitive mye-
loid leukemia cell line K562 and the NK-resistant lymphoma cell 
line Daudi [16,17]. Little is known about the susceptibility of 
human melanoma cells to LAK cells generated by IL-7. We here 
report on the sensitivity of four phenotypically different human 
melanoma cell lines as well as HaCat keratinocytes and human 
endothelial cells to LAK cells induced by IL-7, in comparison to 
IL-2. 
MATERIALS AND METHODS 
Cytokines Human recombinant IL-7 with a specific activity of 4.7 X 107 
U/mg and 3.9 endotoxin-units (EU) per ng protein was provided by Im-
munex (Seattle, W A). The specific activity was determined with a bioassay 
that employs the IL-7 - dependent IxN /Lb pre - B-cellline (8). Human re-
combinant IL-2 with a specific activity of2 X 106 U/mg and < 100 EU/mg 
was purchased from Boehringer, Mannheim, Germany. 
Cell Culture Human melanoma cells were cultured as previously de-
scribed (18) . The permanent melanoma cell lines SK-MEL-23, SK-MEL-37, 
SK-MEL-186, and MeWo were established several years ago at the Memo-
rial Sloan Kettering Cancer Center from metastatic lesions of patients with 
malignant melanoma and have been characterized extensively regarding 
their differentiation markers [19). Melanoma cell lines MeWo and SK-
MEL-23 express melanosomal antigens and are negative for HLA-DR and 
epidermal growth factor (EGF)-receptor expression, whereas SK-MEL-37 
and SK-MEL-186 exhibit the inverse phenotype. HaCat cells, kindly pro-
vided by Dr. N. Fusenig, Heidelberg, Germany, represent a permanent cell 
line that resembles normal keratinocytes in most features. The cells were 
maintained as described (20). Human umbilical vein endothelial cells 
(HUVECs) were purchased from Clonetics (San Diego, CAl and maintained 
as recommended by the distributor. 
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LAK Cell Generation Peripheral blood mononuclear cells (PBMCs). 
obtained from 10 healthy donors by Ficoll-Hypaque centrifugation of 
venous blood. were used as effector cells. The adherent cells (monocytes) 
were removed by incubating the PBMCs in plastic plates for 1 hat 37"C. 
The non-adherent cells (PBLs) were decanted and used for the generation of 
LAK cells. as previously described [21). In short. PBLs were incubated at a 
density of 2 X 106 cells/ml in RPMI-1640 (Gibco, Eggenstein, Germany) 
supplemented with 10% heat-inactivated fetal calf serum (FCS; Seromed. 
Berlin. Germany). 1% pelllclllm/streptomycm (Seromed). and 10% gluta-
mine (Gibco) in the presence ofIL-7 (10-1000 V/ml) orIL-2 (100 V/ml). 
One thousand units IL-7 represented 0.1 Ilg and 100 V IL-2 represented 
0.033 Ilg of each agent. respectively. The PBLs were incubated in 25-c~2 
flasks (Greiner. Frickenhausen. Germany) in an upright position for 4 d m 
5% CO2 at 37"C. On day 4. LAK cell concentration was determined by the 
counting of cells; excluding 0.18% trypan blue dye. 
Cytoxicity Assay LAK activiry against melanoma cells. HaCat keratino-
cytes. and HVVECs was measured by a 24-h tetrazolium-based colorimetric 
cytotoxicity assay using 3-[4.5-dimethythiazol-2-yl)-2.5-diphenyltetrazo-
liUlll bromide (MTT). as described by Mosman and Fong [22.23). The 
principle of the test is based on the selective reduction of the tetrazolium salt, 
MTT. by mitochondrial dehydrogenases. The yellow form of the saltturns 
purple intracellularly. Solubilized formazan crystals can then be quantitated 
spectrophotometrically. and absorbance is proportional to the number of 
viable cells. Modified as a cytoxicity assay for the quantification of antitumor 
effects mediated by human LAK cells on tumor cell targets, this assay has 
been found to compare favorably with the StCr release in terms of sensitivity 
and reproducibility [24]. The test was performed as f~llows . Melanom~ cells, 
HaCat keratinocytes. or HVVECs were brought to smgle-cell suspensIOn by 
incubation with 0.25% trypsin-ethylenediamine tetraacetic acid (EDTA) 
solution (Seromed). Cell concentration and viability were determined by 
hemocytometer counts of cells, excluding 0.18% trypan blue dye. Cells were 
plated at a density of 1 X 10' cells/well in 96-well flat-bottomed tissue 
culture microtiter plates (Greiner) 20 h prior to the addition of effector cells. 
LAK cells were added at different effector : target (E : T) ratios ranging from 
20 : 1 to 2.5 : 1. Quintuplicates were used for each E: T ratio. After incuba-
tion for 24 h. non-adherent cells were removed by performing three consec-
utive washes with unsupplemented medium. Recultivation of detached tar-
get cells was performed to reassure that target cells were damaged lethally. 
Fifry microliters MTT (Sigma, Deisenhofen, Germany) solution at a con-
centration of 5 mg/ml. followed by 150 III of complete medium, were 
added to each well. The plates were incubated in a humidified atmosphere in 
5% CO2 at 37°C. After 4 h, MTT solution was aspirated completely and 
formazan crystals formed in viable cells were solubilized by addition of 
150 JlI dimethylsulfoxide (DMSO) (Merk, Darmstadt. Germany) to each 
well and by repetitive aspiration. Absorbance was read within 1 h at a wave-
length of 540 nm on a scanning multi well spectrophotometer (Titertek 
Multiscan MCC/340. Meckenheim, Germany). The percentage of cell 
deaths (lysis) was determined as 
A-(B-C) 
A X 100 = % specific cell lysis. 
where A is defined as the mean optical density (As.o) of 1 X 10' target cells 
without addition of effector cells. B is the mean experimental absorbance 
As.w of adherent tumor cells remaining in the wells after washing. and C as 
the absorbance As.o of adherent effector cells remaining in the wells after 
washing. To determine nonspecific As.o activity due to adherent LAK cells. 
different numbers of LAK cells were plated into the wells of 96-well micro-
titer plates without any target cells. Intratest standard deviation was below 
10%. 
Tumor Necrosis Factor (TNF)-Alpha Secretion of LAK Cells To 
determine TNF-alpha levels secreted by LAK cells and unstimulated lym-
phocytes. peripheral blood lymphocytes (PBLs) (106 cells/ml) of seven pa-
tients were incubated as described for LAK cell generation. After 4 d of 
incubation. aliquots were removed and tested for TNF-alpha secretion by 
enzyme-linked immunosorbent assay (ELISA) (Quantikine. RD Systems, 
Minneapolis. MN). which had a detection range between 10 and 7500 pg/ 
ml. All tests were performed in quadruplicate and standard deviation was 
below 10%. 
Flow Cytometry After 4 d of culture. lymphocytes were adjusted to the 
concentration of 0.5 X 106 cells/ml in phosphate-buffered saline (PBS) and 
directly stained with the following fluorescein- or phycoerythrin-labeled 
monoclonal antibodies: anti-Leu 4 (CD3). Leu 2a (CD8), Leu 19 (CD56). 
Leu 12 (CD12). and tac (CD25). All monoclonal antibodies were purchased 
from Becton Dickinson, Heidelberg, Germany. Two-color flow cytometry 
analysis was performed on a FACScan (Becton Dickinson). 
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Figure 1. Specific lysis of four different llUman melanoma cell lines by 
IL-7 - and IL-2 - induced LAK cells and unstimulated lymphocytes at an 
E: T ratio of 20: 1. Data are expressed as percent mean lysis of lymphocytes 
from 10 healthy donors by the MTT test. All experiments were performed in 
quintuplicate and have been repeated at least twice. Standard deviation of the 
calculated mean percent cytotoxicity for all donors was below 10%. 
Statistical Analysis Statistical significance of the data was calculated 
using the modified Wilcoxon signed-rank test [25). The procedure is to 
convert the observations to rank order and then calculate the t statistic by 
using ranks instead of the original observations. 
RESULTS 
Sensitivity of Human Melanoma Cells to IL-7 - Induced LAK 
Cells from Healthy Donors IL-7 - induced LAK cells of 10 
healthy donors lysed all four allogeneic human melanoma cell lines 
tested. (Fig 1). Cytotoxicity generated by IL-7 was dose dependent, 
rea~h.mg a plateau at an IL-7 concentration of 1000 U Iml. No 
additIOnal melanoma cell lysis was seen at higher IL-7 concentra-
tions (data not shown). 
L~K cell .activity was also proportional to the E: T ratio, with 
maxlma.1 ~ysls at an effector-target ratio of 20: 1 (Fig 2). The mean 
cytotoxIcIty of IL-7 -lJ1duced LAK cells varied from 41 % (SK-
MEL-37 and SK-MEL-186) to 47% (MeWo) and 52% (SK-MEL-
23). 
Comparison of IL-2 - and IL-7 - Induced LAK Cells LAK 
c.ell activity generated by IL-2 was higher against all melanoma cell 
lme.s ~ested ~o~pared to IL-7 stimulation (p < 0.01) (Fig 1). No 
statIstically slgmficant differences were observed between the sus-
ceptibility of the more differentiated melanoma cell lines SK-Mel 
23 and MeWo and the less differentiated melanoma cell lines SK-
Mel 186 and SK-Mel 37 cells regarding both IL-7 - and IL-2-
induced LAK cells . 
Flow Cytometry Analysis of Effector Cell Population The 
patterns of various cell-surface markers of the LAK cells were stud-
ied using flow cytometry analysis (Table I). The most striking dif-
ference between IL-7 - and IL-2 - induced LAK cells was the higher 
percentage of IL-7-induced CD25-positive (tac antigen, low-af-
finity recepto~ ?fIL-2) LAK-cells. CD 25 was expressed on 35% of 
the CD3-posltlve cells, but on only 3% of the CD3-negative cells. 
Furthermore, 38% of the CD56-negative cells were CD25 positive 
whereas only 2% of CD56-positive cells were CD25 positive. 
These results are consistent with the possibility that IL-7 -induced 
upregulation of CD25 occurs principally on CD3+CD56- cells; 
however, three-color flow cytometric analysis would be necessary 
to validate this possibility more conclusively (Table I) (Figs 3, 4). 
LAK Cell Activity Against HaCat Keratinocytes To evaluate 
possible differences between IL-7 - and IL-2 - induced effector cells 
on keratinocytes, PBLs from seven healthy donors were stimulated 
with 100 U/ml IL-2 or 1000 U/ml IL-7 and then co-incubated 
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Figure 2. Specific lysis ofSK-Mel23 by IL-7- and IL-2-induced LAK 
cells and unstimulated lymphocytes at different E : T ratios. Percent mean 
lysis is shown for one representative donor determined by MTT test. Com-
parable results were obtained for SK-Mel186, SK-Mcl37, and MeWo using 
the same lymphocytes. All experiments were performed in quintuplicate and 
have been repeated at least twice. Standard deviation was below 10% in all 
experiments. 
with HaCat cells (Fig 5). At the highest E : T ratio of 20: 1, IL-7 -
induced LAKactivity was only 30% (range, 11-42%) and compa-
rable to the cytotoxicity mediated by unstimulated PBLs (25%, 
range 9 - 36%; p = NS) . In contrast, non-specific lysis of HaCat 
keratinocytes by LAK cells generated by IL-2 at the same E : T ratio 
was 62% (range 30-91%; p < 0.01). 
LAK Cell Activity Against HUVECs To test the susceptibility 
of human endothelial cells to LAK cell-mediated cytotoxicity, PBLs 
of three donors were stimulated with 100 U/ml IL-2 or 1000 UI 
ml IL-7 . At an E:T ratio of 10 : 1, the mean LAK cell activity of 
unstimulated lymphocytes against HUVECs was 8% (range, 0-
17%). IL-7 - generated LAK cell cytotoxicity was within the same 
range (0 - 14%; mean, 7%). In contrast, IL-2-induced LAK cells 
were highly effective in killing HUVECs (mean, 60%; range, 45-
65%). 
TNF-Alpha Secretion by Lymphokine-Activated PBLs To 
address one possible mechanism involved in the LAK activity, se-
cretion ofTNF-alpha into the culture supernatants ofPBLs of seven 
Table I. Characterization of IL-7 - and IL-2 - Induced LAK 
Cells from Eight Healthy Donors by Flow Cytometry Analysis' 
Phenotype Unstimulated IL-2 (100 U/ml) IL-7 (1000 U/ml) 
CD3+ 76% (66-86%) 82% (70-91%) 77% (63%-87%) 
CD8+ 41% (34 - 50%) 39% (22 - 50%) 45% (39-49%) 
CDS6+ 15% (7-25%) 18% (8-22%) 16% (8-24%) 
CD25+ 13% (3 - 18%) 16% (12-24%) 41% (26-52%) 
CD19+ 3% (3- 5%) 5% (4-8%) 5% (3-8%) 
CDS6+CD3+ 2% (1-12%) 3% (1- 7%) 2% (1-10%) 
CD56+CD3- 13% (6-26%) 18% (12-20%) 17% (7-26%) 
CD56+CD2S+ 1 % (0 - 2%) 2% (0-2%) 2% (1 - 4%) 
CD56-CD2S+ 12% (7-14%) 16% (12-25%) 38% (6-51 %) 
CD3+CD2S+ 8% (3 -12%) 11 % (9 -15%) 35% (23 - 46%) 
CD3-CD2S+ 2% (1-6%) 3%(1-8%) 3% (2-9%) 
CD8+CD25+ 1% (1-4%) 3%(1 - 6%) 9% (6-15%) 
, Mean percent values are given, as arc ranges (in parentheses). 
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Figure 3. Representative flow cytometry analysis of CD56 and CD25 
antigen expression of LAK cells stimulated with IL-7 (1000 U Iml) or IL-2 
(100 U/ml) for 4 d. Unstimulated lymphocytes were used as controls. The 
percentage of gated cells is given for each quadrant. 
donors was determined by enzyme-linked immunosorbent assay 
(ELISA) . Aliquots of the same PBL preparation were tested without 
and after stimulation with IL-2 and IL-7. As shown in Table II, 
TNF-alpha levels secreted from IL-7 - exposed lymphocytes were 
mostly in the same range of unstimulated lymphocytes, with one 
exception (number 2), whereas IL-2 - stimulated LAK cells secreted 
more TNF-alpha compared to unstimulated and IL-7 - generated 
LAK cells in all cases (p < 0.01). Using the Wilcoxon rank test for 
unpaired parameters, we statistically analyzed the data for TNF-a 
secretion upon stimulation individually for each patient. There was 
no statistical difference in TNF levels between PBLs and IL-7-
stimulated LAK cells. However, comparison ofTNF levels secreted 
upon IL-2 stimulation differed significantly from levels of unstimu-
lated PBLs (p < 0.01) and IL-7 -generated LAK cells (p < 0.01). 
Stimu lation by 
unstimulated IL-2 IL-7 
CD25 (FITC-labeled) 
Figure 4. Representative flow cytometry analysis of CD3 and CD2S anti-
gen expression of LAK cells stimulated with IL-7 (1000 U/ml) or IL-2 
(100 U Iml) for 4 d. Unstimulated lymphocytes are shown for control. The 
percentage of gated cells is given for each quadrant. 
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Figure 5. Percent mean lysis of HaCat keratinocytes by IL-7 - and IL-2-
induced LAK cells and by unstimulated lymphocytes as assessed by MTT 
test_ LAK cells were generated by incubating PBLs from seven healthy 
donors with IL-7 (1000 U/ml) or IL-2 (100 U/ml) for 4 d. Ranges a~e 
given at the top of each bar graph. All expe.riments were p~rf?rmed m 
quintuplicate and have been repeated at least twice. Standard deViation of the 
calculated mean percent cytotoxicity for all donors was below 10%. 
DISCUSSION 
After autologous melanoma cells were found in vitro to. be hi~hly 
susceptible to LAK cells gener.at~d by IL-2, this cytob~e gau~ed 
clinical acceptance as an agent 111 Immunotherapy of patients V:lth 
advanced melanoma [1,3,26,27] . Severe toxicity, hov:ever, IS a 
major obstacle to immunotherapy with IL-2. R~c~ntly, It .has been 
demonstrated that IL-7 can induce LAK cell actiVity that IS largely 
independent of IL-2 secretion [17]. In the present study, we ha:re 
shown that IL-7 - induced LAK cells lyse human melanoma .cells I~ 
a dose-dependent manner. However, at the same E: T ratiO, thiS 
LAK activity is only half as high as that ofIL-2 -l11duce? LAK cells. 
This is in accordance with data from others who descnbed a 5 - 10 
rimes lower LAK cell activity ofIL-7 - induced LAK cells compared 
to IL-2-induced LAK cells when Daudi cells were used as target 
cells and cytotoxicity was measured with the SICr relea~e assay J16] . 
No major differences in the susceptibility of phenotypically differ-
ent melanoma cell lines to LAK cells induced by IL-7 or IL-2 were 
obvious. 
Natural killer (NK) cells are suggested to be the predominant 
precursor cell population of LAK cells generated by either IL-2 or 
IL-7 [17]. The phenotypic characterization of surface markers of 
LAK cells generated by IL-7 or IL-2 revealed d.ifferences in the 
expression of cell-surface molecules (Table I), particularly o~ CD25 
(Tac antigen, low-affinity form of the 11:-2 receptor), whlCh was 
expressed more markedly on LAK cells stimulated by IL-7 express-
ing the phenotypic characteristics CD56- or CD3+. ~s no three-
color fluorescence-activated cell sorter (FACS) analYSIS has been 
performed, the conclusion that CD25 upregulati?n ?cc~rred on 
LAK cells with a CD56- CD3+ phenotype remal.ns mdlrect. ~n­
creased expression of CD25 on LAK cells upon st1l1mlatIOn With 
IL-7 was observed previously by others to be even more prono~nced 
than after IL-2 stimulation [16,17,33]' in line with a preVIOusly 
reported increased upregulation?f CD25 by. IL-7 on ~BMCs and T 
cells [9,12] . Because the expresslOn.of the lllg~-affi':lty IL-2 recep-
tor has been shown to be involved 111 the proliferation of NK cells 
[32]. it was suggested that the upregulation o~ ~he IL-2 receptor by 
IL-7 would make susceptible cells more sensitive to IL.-2 [17] .. Al-
though IL-2- induced LAK activity is commonly assOCiated With a 
CD56+ CD3- phenotype, it is clear that at least some of the large 
granular lymphocytes exhibiting CD3 eXfression ~lso have th~ po-
tential for mediating cytotoxic actions [34 . It remal11S to be clanfied 
whether and how the increase in the CD25+ ICD3+ but CD56-
IL-7 INDUCES LAK CELLS 841 
Table II. Secretion ofTNF-Alpha (in pgjml) by PBLs upon 
Stimulation with 100 IU/ml IL-2 and 1000 IU/ ml IL-7 in Seven 
Normal Donors, Determined in Quadruplicate by ELISA" 
Unstimulated 
Donor PBL IL-2 IL-7 
1 392 475 320 
2 50 1750 1055 
3 15 70 15 
4 150 172 138 
5 155 785 205 
6 85 176 90 
7 100 340 220 
• Standard deviation was below 10%. 
subpopulation in IL-7 - generated LAK cell cui tures contributes di-
rectly or indirectly to the total LAK cell activity generated by IL-7. 
Recently, it has been shown that IL-2-induced LAK cells possess 
an indiscrirninative lytic potential that does not seem to be specific 
for tumor targets [29 - 31]. Numerous significant side effects have 
been reported during high-dose immunotherapy with IL-2 and are 
thought to be related in part to the cytotoxic effects of IL-2-
induced LAK cells towards normal cells, including endothelial cells 
and keratinocytes. The present comparative studies of IL-7 - and 
IL-2 - induced LAK cells demonstrate that IL-7 - induced LAK cells 
are far less cytotoxic against normal H aCat keratinocytes and 
human endothelial cells than are IL-2 - induced LAK cells. LAK cell 
activity against HaCat keratinocytes and HUVECs was in the range 
of unstimulated PBLs, in contrast to a lysis of more than 60% me-
diated by IL-2 - induced LAK cells. Whether this interesting find-
ing reflects the overall weaker cytotoxicity ofIL-7 - induced LAK 
cells compared to IL-2 - induced LAK cells or a more discriminative 
tumor-cell- killing behavior of LAK cells generated by IL-7 needs 
further elucidation. 
Because TNF-alpha is incriminated as one of the cytokines in-
duced secondarily during immunotherapy with IL-2 and because it 
appears to be responsible in part for the vascular leakage syndrome, 
we determined the TNF-alpha secretion from PBLs with and with-
out stimulation. Although one of seven patients analyzed showed a 
substantial TNF response to IL-7 - albeit weaker compared to IL-2 
- TNF-alpha levels ofIL-7 - induced LAK cells were in most cases 
in the range of unstimulated lymphocytes, whereas they were sig-
nificantly increased after IL-2 stimulation. This is in accordance 
with the observation that immunomagnetically purified CD56+ 
lymphocytes secrete 50 times less TNF-alpha after stimulation with 
IL-7 compared to IL-2, although they are almost as cytotoxic as 
IL-2-induced LAK cells [33]. IL-7 is thus likely to have a higher 
therapeutic index than IL-2 in immunotherapy of malignant mela-
noma. The present findings therefore warrant further studies with 
IL-7, including in vitro experiments with autologous melanoma 
cells and preclinical pilot studies in patients with advanced malig-
nant melanoma. 
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